- Home
- BOLD vs RLYB Comparison
BOLD vs RLYB Comparison
Compare BOLD & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | RLYB |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 28.7M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BOLD | RLYB |
|---|---|---|
| Price | $1.28 | $0.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 119.5K | ★ 208.0K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $1.00 | $0.22 |
| 52 Week High | $2.77 | $1.08 |
Technical Indicators
Market Signals| Indicator | BOLD | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 52.50 |
| Support Level | $1.14 | $0.67 |
| Resistance Level | $1.24 | $0.72 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 62.00 | 47.05 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.